4.5 Article

Antibacterial activity and physicochemical characterization of calcium-aluminium-ciprofloxacin-layered double hydroxide

Journal

Publisher

ELSEVIER
DOI: 10.1016/j.jddst.2020.102314

Keywords

Calcium-aluminium-layered double hydroxide; Ciprofloxacin; Antibacterial drug; Controlled release; Drug delivery system

Funding

  1. UiTM Internal Grant, Research Entity Initiative (REI) [600-IRMI/REI 5/3 (008/2019)]

Ask authors/readers for more resources

In this study, ciprofloxacin was successfully intercalated into calcium-aluminium-layered double hydroxide as a potential new carrier for the drug. Various analyses confirmed the successful intercalation and highlighted the potential applications of CAL as a carrier for ciprofloxacin.
A fluoroquinolone antibacterial drug, ciprofloxacin (CPX) was successfully intercalated into calcium-aluminium-layered double hydroxide (CAL) with a molar ratio of 3:1 (Ca:Al) by anion-exchange method. The successful intercalation was confirmed by powder X-ray diffraction (PXRD) pattern analysis, Fourier transform infrared spectroscopy (FTIR), elemental analysis (CHNS), and inductively coupled plasma-atomic emission spectrometry (ICP-AES). The material was also characterized by using field emission scanning electron microscope (FESEM), transmission electron microscopy (TEM), and accelerated surface area and porosity (ASAP) analysis. The basal spacing of calcium-aluminium-ciprofloxacin-layered double hydroxide (CAC) synthesized in this study is 16.2 angstrom, which resulted from the expansion of CAL due to the inclusion of CPX in the interlayer space of the CAL carrier with a loading percentage of 75.9% (w/w). The FTIR spectra of CAC show resemblance to the peaks of CAL and CPX, indicating the inclusion of the drug into the CAL interlayers. The release percentages of the drug into phosphate-buffered saline (PBS) at pH 4.8 and 7.4 are 67% and 60%, respectively, and are best described by the pseudo-second order kinetic model. The antimicrobial activity of CPX, CAL, and CAC were investigated against Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus. CAL has a prospective application as a new carrier for CPX.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available